NCT04373083View on ClinicalTrials.gov

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

November 15, 2020

Primary Completion Date

December 20, 2022

Study Completion Date

February 20, 2025

Conditions

Hodgkin Lymphoma

Interventions

DRUG

Cemiplimab

Administered in 3-week intervals

RADIATION

Involved-site radiotherapy (IS-RT)

Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol